Website address:
https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases

Next milestone in the treatment of liver tumors and acute and chronic liver diseases

The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and liver transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the administered drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of liver cells. The study results have now been published in the renowned scientific journal CELL.

The preclinical and phase I studies were made possible by a collaboration led by Prof. Dr. Lars Zender, Medical Director of the Department of Medical Oncology and Pneumology at Tuebingen University Hospital and Tuebingen scientists, the Tuebingen start-up HepaRegeniX and researchers from the Mayo Clinic (USA).

Preclinical studies in animal models have shown that the increased liver regeneration caused by HRX-215 could allow liver surgery that was previously not possible. For example, in cases of advanced liver tumors, it has not been possible to remove all of the diseased tissue because doing so would cause the remaining liver to fail. Even individuals with advanced liver tumors may now be able to have them totally removed thanks to HRX-215's potential to rapidly boost liver regeneration. Furthermore, the active substance would be able to provide more people with a life-saving liver transplant. A phase I study in 48 healthy volunteers showed excellent safety and tolerability of the drug.

Liver diseases as a growing health problem

Liver diseases are a global health problem and are responsible for more than two million deaths per year. The number of deaths has risen by 50 percent in recent decades and is expected to double in the next 20 years. Although the liver is an organ that can regenerate itself, this property has its limits. Particularly in chronic and acute liver diseases or after the surgical removal of a large part of the organ, the liver cells can no longer regenerate sufficiently, resulting in often fatal liver failure. Liver transplantation remains the last option for patients with end-stage liver disease; however, only ten percent of affected patients are able to receive a life-saving liver transplant due to organ scarcity.

Clinical results give reason for hope

As there were previously no drugs that could increase the regeneration of a damaged liver, the results published in Cell with the new drug HRX-215 are a milestone: "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of acute liver diseases," emphasizes Dr. Wolfgang Albrecht, Managing Director of the Tuebingen-based start-up company HepaRegeniX. The current results and the spin-off of HepaRegeniX were largely made possible by a groundbreaking discovery of Lars Zender and his laboratory in 2013. "By inhibiting the kinase MKK4, the self-healing function of a damaged liver can be triggered," says first author Stefan Zwirner, summarizing the findings.

Possible solution to organ donation shortage?

"HRX-215 would not only be an urgently needed treatment option in the surgical removal of liver tumors, but would also be able to help overcome the major problem of organ shortage in the field of liver transplantation," Prof. Zender points out the possible applications. Living transplants from the smaller left part of a healthy donor's liver would be a solution, as removal poses little health risk for healthy donors. However, this part of the liver is often too small to take over the function of the liver that was removed from the recipient. "Due to the rapid enhancement of liver regeneration mediated by HRX-215, we assume that HRX-215 treatment would enable the safe transplantation of small left liver lobes in normal size adults," Prof. Zender continues. However, clinical studies will have to show this in the future.

Tuebingen Center for Academic Drug Discovery & Development

"When we started developing an MKK4 inhibitor in 2017, none of us imagined that we would be able to start the first clinical trial just four years later and even present the first results of the Phase I trial three years later," adds Prof. Stefan Laufer, whose research group carried out the medicinal chemistry work on the first MKK4 inhibitor. The development of MKK4 inhibitors is a success story and underlines Tuebingen's national and international leading role in the field of drug discovery and development. With the Cluster of Excellence "iFIT" (Image Guided and Functionally Instructed Tumor Therapies) and the "Tuebingen Center for Academic Drug Discovery & Development" (TüCAD2), whose founder and spokesperson Professor Laufer is, the university has a unique platform in the field of identification, validation and development of innovative drug candidates, which has already brought several candidates to first application in humans.

German-American cooperation

Before the active substance was tested in healthy volunteers within the Phase I study, it was investigated in animal models. For the latter, Tuebingen collaborated with Prof. Dr. Scott. L. Nyberg from Mayo Clinic, an expert in the field of transplantation and regenerative medicine. The preclinical study was able to show that the use of HRX-215 increased liver regeneration and prevented liver failure, even after removal of 85 percent of the organ. “This research is significant because this is the first drug of its kind to show an increase in healing and regeneration of the liver after major surgery. This discovery has the potential to improve the treatment of liver failure, increase the safety of liver transplantation for living donors and potentially avoid the need for a liver transplant in some cases,” says Nyberg, co-senior author of the study.

Publication:
First-in-class MKK4 Inhibitors enhance Liver Regeneration and prevent Liver Failure DOI: https://dx.doi.org/10.1016/j.cell.2024.02.023

Press release

14-Mar-2024
Source: Tuebingen University Hospital

Further information

Prof. Dr. Lars Zender
Medical Oncology and Pneumology (Internal Medicine VIII)
Medical Director

- University Hospital Tübingen
- HepaRegeniX

More about HepaRegeniX in our article:

HepaRegeniX develops an active substance for liver regeneration

When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.